Get the Stockscreener App
3.21
2.72%
0.085
After Hours:
3.21
Eupraxia Pharmaceuticals Inc stock is traded at $3.21, with a volume of 8,215.
It is up +2.72% in the last 24 hours and up +5.25% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
See More
Previous Close:
$3.125
Open:
$3.18
24h Volume:
8,215
Relative Volume:
0.51
Market Cap:
$114.35M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.85%
1M Performance:
+5.25%
6M Performance:
+34.31%
1Y Performance:
+0.00%
1-Day Range:
$3.12
$3.2799
1-Week Range:
$2.845
$3.2799
52-Week Range:
$2.20
$4.08
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.21 | 114.35M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Knee Osteoarthritis Pipeline 2024: Key Companies, MOA, ROA, - openPR
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.5% – Time to Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.5%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.5% – Here’s What Happened - Defense World
Eupraxia Pharmaceuticals Inc - Stockhouse Publishing
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Up 1.7% – Still a Buy? - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Increase in Short Interest - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Growth in Short Interest - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 1% – Should You Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.3% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) & Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Financial Analysis - Defense World
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - The Eastern Progress Online
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Re - GuruFocus.com
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brok - GuruFocus.com
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Eupraxia Pharmaceuticals Strengthens Senior Management Team - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
Eupraxia Pharma Shares Jump Following Data From Eosinophilic Esophagitis Trial - MarketWatch
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - The Malaysian Reserve
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Re - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail
Eupraxia Pharmaceuticals to Present at American College of Rheum - GuruFocus.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eupraxia Pharmaceuticals files report with SEC - Investing.com
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Australia
RODMAN&RENSHAW Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to "Strong-Buy" - MarketBeat
Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - Canada NewsWire
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat
Eupraxia Pharmaceuticals reports regulatory update - Investing.com
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 – Company AnnouncementFT.com - Financial Times
Newswire - KelownaNow
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Malaysian Reserve
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Finansavisen - Finansavisen
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Yahoo Finance
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper
Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
There is no financial data for Eupraxia Pharmaceuticals Inc (EPRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):